Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmstandard JSC
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”
Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.
- Research, Analytical Equipment & Supplies
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Other Names / Subsidiaries
- Phs-Leksredstva JSC
- Pharmstandard-UfaVITA JSC
- PHS-Tomskhimpharm JSC
- LEKKO CJSC
- Biomed Mechnikov JSC
- Pharmstandard OJSC